Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Román Pérez, Erick ^a   Casbas Hernández, Patricia ^b   Pirone, Jason R ^c   Rein, Jessica ^c   Carey, Lisa A ^c   Lubet, Ronald A ^d   Mani, Sendurai A ^e,f   Amos, Keith D ^b,c   Troester, Melissa A ^a,c  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; ESTROGEN; ESTROGEN RECEPTOR; RNA; TRANSFORMING GROWTH FACTOR BETA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST FIBROSIS; CANCER PROGNOSIS; CELL ACTIVATION; CELL ADHESION; CELL CONTACT; CELL MOTION; EXTRATUMOR MICROENVIRONMENT; FEMALE; FIBROBLAST; GENE; GENE CLUSTER; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TWIST RELATED PROTEIN 1 GENE; BREAST TUMOR; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLAUDINS; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT; TWIST TRANSCRIPTION FACTOR;

EID: 84859942660     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3152     Document Type: Article

References (46)

1. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527. 10.1038/nm1764, 18438415.
2. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7. 10.1371/journal.pbio.0020007, 314300, 14737219.
3. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res 2009, 15:778-787. 10.1158/1078-0432.CCR-08-1283, 2987696, 19188147.
4. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 2008, 88:591-601. 10.1038/labinvest.2008.31, 18414401.
5. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11:R7. 10.1186/bcr2222, 2687710, 19187537.
6. Schedin P, Borges V. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Res 2009, 11:102. 10.1186/bcr2235, 2688940, 19344495.
7. Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS. Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 2009, 15:7020-7028. 10.1158/1078-0432.CCR-09-1126, 2783932, 19887484.
8. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2009, 123:397-404. 2976659, 19949854.
9. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32. 10.1016/j.ccr.2004.06.010, 15261139.
10. Cichon M, Degnim A, Visscher D, Radisky D. Microenvironmental Influences that Drive Progression from Benign Breast Disease to Invasive Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 2010, 15:389-397. 10.1007/s10911-010-9195-8, 3011086, 21161341.
11. de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 2011, 125:687-696. 10.1007/s10549-010-0855-6, 20361254.
12. Chen DT, Nasir A, Venkataramu C, Fulp W, Gruidl M, Yeatman T. Evaluation of malignancy-risk gene signature in breast cancer patients. Breast Cancer Res Treat 2009, 120:25-34. 2808422, 19306088.
13. Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL. Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17:236-246.
14. Heaphy CM, Griffith JK, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 2009, 118:229-239. 10.1007/s10549-009-0504-0, 19685287.
15. Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP. Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 2006, 119:376-388. 10.1007/s00439-006-0135-z, 16485136.
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
17. Proia DA, Kuperwasser C. Reconstruction of human mammary tissues in a mouse model. Nat Protoc 2006, 1:206-214. 10.1038/nprot.2006.31, 17406234.
18. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol Cancer Res 9:3-13.
19. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
20. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
21. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107:15449-15454.
22. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008, 26:4078-4085. 10.1200/JCO.2007.13.4429, 2654368, 18757322.
23. Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X, Perou C. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
24. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664. 10.1200/JCO.2005.03.2755, 16505416.
25. Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 4:3.
26. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
27. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001, 7:1267-1278. 10.1016/S1097-2765(01)00260-X, 11430829.
28. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 2008, 367:235-241. 10.1016/j.bbrc.2007.11.151, 2696127, 18062917.
29. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997, 273:F563-574.
30. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995, 130:393-405. 10.1083/jcb.130.2.393, 2199940, 7615639.
31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
32. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17:320-329.
33. Sieweke M, Thompson N, Sporn M, Bissell M. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science 1990, 248:1656-1660. 10.1126/science.2163544, 2163544.
34. Rossner P, Gammon MD, Zhang YJ, Terry MB, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Kalra TS, Gaudet MM, Teitelbaum SL, Neugut AI, Santella RM. Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 2009, 13:3847-3857. 10.1111/j.1582-4934.2008.00553.x, 2832100, 19602056.
35. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002, 347:1566-1575. 10.1056/NEJMoa021153, 12432043.
36. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 2009, 11:202. 10.1186/bcr2224, 2687712, 19291273.
37. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851. 10.1126/science.1090922, 14764882.
38. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 2009, 119:1571-1582. 10.1172/JCI37480, 2689133, 19451693.
39. Foubert E, De Craene B, Berx G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res 2010, 12:206. 10.1186/bcr2585, 2917026, 20594364.
40. Sehgal PB. Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells. Oncogene 2010, 29:2599-2600. author reply 2601-2593, 10.1038/onc.2010.4, 2861727, 20140019.
41. Tuhkanen H, Soini Y, Kosma VM, Anttila M, Sironen R, Hamalainen K, Kukkonen L, Virtanen I, Mannermaa A. Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer 2009, 9:289. 10.1186/1471-2407-9-289, 3087336, 19695091.
42. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
43. Haakensen VD, Lingjaerde OC, Luders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, Borresen-Dale AL, Helland A. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Med Genomics 2011, 4:77. 10.1186/1755-8794-4-77, 3216859, 22044755.
44. Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, Ashida A, Daiko H, Ochiai A, Muto M, Ohtsu A, Yoshida T, Sasaki H. Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research. PLoS One 2011, 6:e18196. 10.1371/journal.pone.0018196, 3080870, 21533028.
45. Trujillo KA, Heaphy CM, Mai M, Vargas KM, Jones AC, Vo P, Butler K, Joste N, Bisoffi M, Griffith JK. Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 129:1310-1321.
46. Wu JM, Beck AH, Pate LL, Witten D, Zhu SX, Montgomery KD, Allison KH, van de Rijn M, West RB. Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes. Clin Cancer Res 17:437-446.